Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Vesicular stomatitis virus-based vaccine protects hamsters against lethal challenge with Andes virus.

Brown KS, Safronetz D, Marzi A, Ebihara H, Feldmann H.

J Virol. 2011 Dec;85(23):12781-91. doi: 10.1128/JVI.00794-11. Epub 2011 Sep 14.

2.

Long-term single-dose efficacy of a vesicular stomatitis virus-based Andes virus vaccine in Syrian hamsters.

Prescott J, DeBuysscher BL, Brown KS, Feldmann H.

Viruses. 2014 Jan 31;6(2):516-23. doi: 10.3390/v6020516.

3.

Adenovirus vectors expressing hantavirus proteins protect hamsters against lethal challenge with andes virus.

Safronetz D, Hegde NR, Ebihara H, Denton M, Kobinger GP, St Jeor S, Feldmann H, Johnson DC.

J Virol. 2009 Jul;83(14):7285-95. doi: 10.1128/JVI.00373-09. Epub 2009 Apr 29.

4.

Immune serum produced by DNA vaccination protects hamsters against lethal respiratory challenge with Andes virus.

Hooper JW, Ferro AM, Wahl-Jensen V.

J Virol. 2008 Feb;82(3):1332-8. Epub 2007 Nov 21.

5.

DNA vaccine-generated duck polyclonal antibodies as a postexposure prophylactic to prevent hantavirus pulmonary syndrome (HPS).

Brocato R, Josleyn M, Ballantyne J, Vial P, Hooper JW.

PLoS One. 2012;7(4):e35996. doi: 10.1371/journal.pone.0035996. Epub 2012 Apr 27.

6.

Active and passive vaccination against hantavirus pulmonary syndrome with Andes virus M genome segment-based DNA vaccine.

Custer DM, Thompson E, Schmaljohn CS, Ksiazek TG, Hooper JW.

J Virol. 2003 Sep;77(18):9894-905.

7.

Induction of protective immunity in a Syrian hamster model against a cytopathogenic strain of Andes virus.

Martinez VP, Padula PJ.

J Med Virol. 2012 Jan;84(1):87-95. doi: 10.1002/jmv.22228.

PMID:
22095538
8.

Depletion of Alveolar Macrophages Does Not Prevent Hantavirus Disease Pathogenesis in Golden Syrian Hamsters.

Hammerbeck CD, Brocato RL, Bell TM, Schellhase CW, Mraz SR, Queen LA, Hooper JW.

J Virol. 2016 Jun 24;90(14):6200-15. doi: 10.1128/JVI.00304-16. Print 2016 Jul 15.

9.

In vitro and in vivo activity of ribavirin against Andes virus infection.

Safronetz D, Haddock E, Feldmann F, Ebihara H, Feldmann H.

PLoS One. 2011;6(8):e23560. doi: 10.1371/journal.pone.0023560. Epub 2011 Aug 10.

10.

Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins.

DeBuysscher BL, Scott D, Marzi A, Prescott J, Feldmann H.

Vaccine. 2014 May 7;32(22):2637-44. doi: 10.1016/j.vaccine.2014.02.087. Epub 2014 Mar 12.

11.

Protective efficacy of a bivalent recombinant vesicular stomatitis virus vaccine in the Syrian hamster model of lethal Ebola virus infection.

Tsuda Y, Safronetz D, Brown K, LaCasse R, Marzi A, Ebihara H, Feldmann H.

J Infect Dis. 2011 Nov;204 Suppl 3:S1090-7. doi: 10.1093/infdis/jir379.

12.

Andes virus M genome segment is not sufficient to confer the virulence associated with Andes virus in Syrian hamsters.

McElroy AK, Smith JM, Hooper JW, Schmaljohn CS.

Virology. 2004 Aug 15;326(1):130-9.

13.

The adaptive immune response does not influence hantavirus disease or persistence in the Syrian hamster.

Prescott J, Safronetz D, Haddock E, Robertson S, Scott D, Feldmann H.

Immunology. 2013 Oct;140(2):168-78. doi: 10.1111/imm.12116.

14.

A novel Sin Nombre virus DNA vaccine and its inclusion in a candidate pan-hantavirus vaccine against hantavirus pulmonary syndrome (HPS) and hemorrhagic fever with renal syndrome (HFRS).

Hooper JW, Josleyn M, Ballantyne J, Brocato R.

Vaccine. 2013 Sep 13;31(40):4314-21. doi: 10.1016/j.vaccine.2013.07.025. Epub 2013 Jul 24.

15.

Antiviral Biologic Produced in DNA Vaccine/Goose Platform Protects Hamsters Against Hantavirus Pulmonary Syndrome When Administered Post-exposure.

Haese N, Brocato RL, Henderson T, Nilles ML, Kwilas SA, Josleyn MD, Hammerbeck CD, Schiltz J, Royals M, Ballantyne J, Hooper JW, Bradley DS.

PLoS Negl Trop Dis. 2015 Jun 5;9(6):e0003803. doi: 10.1371/journal.pntd.0003803. eCollection 2015.

16.

Construction and nonclinical testing of a Puumala virus synthetic M gene-based DNA vaccine.

Brocato RL, Josleyn MJ, Wahl-Jensen V, Schmaljohn CS, Hooper JW.

Clin Vaccine Immunol. 2013 Feb;20(2):218-26. doi: 10.1128/CVI.00546-12. Epub 2012 Dec 12.

17.

A pseudotype vesicular stomatitis virus containing Hantaan virus envelope glycoproteins G1 and G2 as an alternative to hantavirus vaccine in mice.

Lee BH, Yoshimatsu K, Araki K, Okumura M, Nakamura I, Arikawa J.

Vaccine. 2006 Apr 5;24(15):2928-34. Epub 2006 Jan 6.

PMID:
16426712
18.
19.

Cross-protection against challenge with Puumala virus after immunization with nucleocapsid proteins from different hantaviruses.

de Carvalho Nicacio C, Gonzalez Della Valle M, Padula P, Björling E, Plyusnin A, Lundkvist A.

J Virol. 2002 Jul;76(13):6669-77.

20.

Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.

Braxton CL, Puckett SH, Mizel SB, Lyles DS.

J Virol. 2010 Apr;84(7):3552-61. doi: 10.1128/JVI.01572-09. Epub 2010 Jan 20.

Supplemental Content

Support Center